



STATE OF CONNECTICUT

DEPARTMENT OF PUBLIC HEALTH
IMMUNIZATION PROGRAM

**PLEASE COPY THIS FOR ALL HEALTH CARE PROVIDERS
IN YOUR PRACTICE**

TO: All Users of State Supplied Vaccines

FROM: Vincent Sacco 
Immunization Program Manager

Lynn Sosa, M. 
Deputy State Epidemiologist

DATE: March 8, 2010

SUBJECT: New Pneumococcal 13-Valent Conjugate Vaccine (PCV 13) available April 1st

On February 24, 2010, the Food and Drug Administration licensed a new pneumococcal conjugate vaccine, brand name Prevnar 13, for the prevention of invasive disease caused by 13 serotypes of *Streptococcus pneumoniae* (CPT Code 90670). PCV 13 is manufactured by Pfizer and is approved for use in children 6 weeks through 5 years of age. PCV 13 contains the same 7 serotypes found in the current formulation of Prevnar but with six additional serotypes. The Advisory Committee on Immunization Practices provisional recommendation for PCV 13, including the dosing schedule, is attached (also available at: <http://www.cdc.gov/vaccines/recs/provisional/downloads/pcv13-mar-2010-508.pdf>). The schedule for PCV 13 is the same as that of PCV 7: four doses administered at 2, 4, 6, and 12–15 months of age. Children who have received one or more doses of Prevnar can complete their 4 dose series with PCV 13. Those children 15 months up to 5 years of age who have received 4 doses of Prevnar may receive an additional dose of PCV 13 to elicit immune responses to the six additional serotypes. The vaccine is supplied in 0.5mL single dose pre-filled syringes (10 per package) and must be refrigerated at 36–46 degrees Fahrenheit or 2–8 degrees Celsius. The complete prescribing information can be accessed at www.prevnar13.com.

Current Supply of PCV 7

PCV 13 will be made available to order beginning April 1, 2010 for your VFC-eligible population 6 weeks–59 months of age. As a reminder, VFC-eligible children include children who are: 1) enrolled in Medicaid; 2) uninsured; 3) American Indian or Alaskan Native; or 4) underinsured (children whose health insurance does not include vaccinations). Once the transition to PCV 13 is made we will no longer supply PCV 7.

You can order and report doses administered of PCV 13 in the same space on the order form you currently use. **PCV 7 orders for the month of March will be adjusted to allow each provider approximately a 6 week supply of vaccine in order to ease your transition over to PCV 13. Your current inventory of PCV 7 should be fully used up before beginning to vaccinate with PCV 13.** Attached is an updated vaccine eligibility form for your records.

As always, if you have any questions, please contact the Immunization Program at (860) 509-7929.

**Vaccine for Children's Program (VFC)
Eligibility Criteria for State of CT provided vaccines April 2010**

Vaccine	Age Group	VFC Status of Children		CPT Code(s)
		VFC-Eligible ¹	Non-VFC Children	
Varicella Dose 1 Dose 2	12 months-18 years ² 15 months-18 years	YES YES	YES YES	90716 90716
Hepatitis B	Newborns in hospital Children 0-18 years	YES YES	YES YES	90744 90744
Td	Children 7-18 years ³	YES	YES	90714
MMR (Doses 1 & 2)	12 months-18 years College entry	YES YES	YES YES	90707 90707
Pneumococcal Conjugate Vaccine	6 weeks-71 months	YES	NO	90670
Influenza	6 months-18 years	YES	NO	90655 90656 90657 90658 90660
DTaP	2 months – 6 years	YES	YES	90700
Hib	2-59 months	YES	YES	90647 90648
IPV	2 months-18 years	YES	YES	90713
DTaP/IPV/Hep B	2 months-6 years	YES	YES	90723
Meningococcal Conjugate Vaccine (MCV4)	11-18 years	YES	YES	90734
Tdap	11-12 years 13-18 years ⁴	YES YES	YES YES	90715 90715
Hepatitis A	12 months-18 years	YES	NO	90633
Rotavirus	6 weeks-8 months	YES	YES	90681
DTaP/IPV	4-6 years	YES	YES	90696
HPV	9-18 years	YES	NO	90649
DTaP/IPV/Hib	2-59 months	YES	YES	90698

1 VFC eligibility is defined as follows: (a) Medicaid enrolled; (b) NO health insurance; or (c) American Indian or Alaskan native. In addition those individuals who are underinsured (have health insurance that does not fully cover immunizations) can be referred to a Federally Qualified Health Center (FQHC) to be immunized with VFC-supplied vaccine. Non-VFC Children refers to patients who have private insurance that fully covers the cost of immunizations.

2 Susceptible children who do not have a clinical history of chicken pox.

3 Td vaccine can be given to children 7-18 years of age to complete their primary series, or to those children 10-18 years old who are in need of a Tetanus containing vaccine and cannot receive Tdap.

4 A single dose of Tdap can be given to 13-18 year olds who are eligible for a Tetanus Diphtheria containing vaccine.

Revised 3/2/10

ACIP Provisional Recommendations for Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Among Infants and Children

Date of ACIP vote: February 24, 2010

Date of posting of provisional recommendations: March 3, 2010

Scheduled date of publication of recommendations in CDC Morbidity and Mortality Weekly Report: March 12, 2010

On February 24, 2010, the ACIP voted on recommendations for use of the new 13-valent pneumococcal conjugate vaccine (PCV13) among infants and children.

The ACIP recommends PCV13 for all children 2 through 59 months of age and for children 60 through 71 months of age who have underlying medical conditions that increase their risk of pneumococcal disease or complications.

1. Infants and children who have not previously received PCV7 or PCV13
 - o The ACIP recommendation for use of PCV13 and the immunization schedules for infants and toddlers 2 through 59 months of age who have not received any prior PCV7 or PCV13 doses are the same as those previously published for PCV7 with PCV13 replacing PCV7 for all doses (MMWR 2000; 49 (RR-9)).

Infants 2 through 6 months of age

- o PCV13 is recommended as a 4-dose series at 2, 4, 6, and 12 through 15 months. Infants receiving their first dose at age <6 months should receive 3 doses of PCV13 at intervals of approximately 8 weeks (the minimum interval is 4 weeks). Minimum age for administration of first dose is 6 weeks. The fourth dose is recommended at age 12 through 15 months and should be given at least 8 weeks after the third dose (Table 1).

Unvaccinated children 7 months of age and older

Infants 7 through 11 months of age

- Three doses are recommended. The first 2 doses should be given with an interval of at least 4 weeks between doses. The third dose should be given at age 12 through 15 months, at least 8 weeks after the second PCV13 dose (Table 1).

Children 12 through 23 months of age

- Two doses are recommended, with an interval of at least 8 weeks between doses (Table 1).

Children 24 months of age and older

- Unvaccinated healthy children 24 through 59 months of age should receive a single dose of PCV13. Unvaccinated children 24 through 71 months of age with underlying medical conditions should receive 2 doses of PCV13 with an interval of at least 8 weeks between doses (Table 2).

2. Children incompletely vaccinated with PCV7 or PCV13

Children <24 months of age

- o Infants and children <24 months of age who have received one or more doses of PCV7 should complete the immunization series with PCV13 (Table 1).

Children >24 months of age

- o A single dose of PCV13 is recommended for all healthy children 24 through 59 months of age with any incomplete PCV schedule (PCV7 or PCV13) (Table 2).
- o For children 24 through 71 months of age with underlying medical conditions who have received any incomplete schedule of <3 doses of PCV (PCV7 or PCV13), 2 doses of PCV13 are recommended. For children with underlying medical conditions who have received 3 doses of PCV (PCV7 or PCV13), a single dose of PCV13 is recommended through 71 months of age (Table 2).

- The minimum interval between doses is 8 weeks.
3. Children completely vaccinated with PCV7
 - A single supplemental dose of PCV13 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7) (Tables 1 and 2).
 - For children who have underlying medical conditions, a single supplemental PCV13 dose is recommended through 71 months of age (Table 2). This includes children who have previously received the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
 - PCV13 should be given at least 8 weeks after the last dose of PCV7 or PPSV23.
 4. Children 6 through 18 years of age with high risk conditions
 - A single dose of PCV13 may be administered for children 6 through 18 years of age who are at increased risk for invasive pneumococcal disease because of sickle cell disease, HIV-infection or other immunocompromising condition, cochlear implant or cerebrospinal fluid leaks, regardless of whether they have previously received PCV7 or PPSV23.
 5. Use of PPSV23 among children 2 through 18 years of age who are at increased risk for invasive pneumococcal disease
 - In addition to receiving PCV13, children with underlying medical conditions should receive PPSV23 at age 2 years or as soon as possible after the diagnosis of chronic illness is made in children >2 years.
 - Doses of PCV13 should be completed before PPSV23 is given.
 - The minimum interval is at least 8 weeks after the last dose of PCV13.
 - However, children who have previously received PPSV23 should also receive the recommended PCV13 doses.
 - A second dose of PPSV23 is recommended 5 years after the first dose of PPSV23 for children who have sickle cell disease, or functional or anatomic asplenia, HIV-infection, or other immunocompromising condition
 - No more than two PPSV23 doses are recommended.

Additional information

- The PCV13 Vaccine Information Statement is available at:
<http://www.cdc.gov/vaccines/pubs/vis/default.htm>
- Details of the routine pneumococcal conjugate vaccination schedule are available at:
<http://www.cdc.gov/vaccines/recs/schedules/default.htm#child>

Table 1. Recommended schedules for administering doses of PCV13 to children <24 months of age by PCV vaccination history and age

Age at examination (mos)	Vaccination history: total number of PCV7 and/or PCV13 doses received previously	Recommended PCV13 Regimen ¹
2 through 6 mos	0 doses	3 doses, 8 weeks apart; fourth dose at age 12-15 mos
	1 dose	2 doses, 8 weeks apart; fourth dose at age 12-15 mos
	2 doses	1 dose, 8 weeks after the most recent dose; fourth dose at age 12-15 mos
7 through 11 mos	0 doses	2 doses, 8 weeks apart; third dose at 12-15 mos
	1 or 2 doses before age 7 mo	1 dose at age 7-11 mos, with a second dose at 12-15 mos, \geq 8 weeks later
12 through 23 mos	0 doses	2 doses, \geq 8 weeks apart
	1 dose before age 12 mo	2 doses, \geq 8 weeks apart
	1 dose at \geq 12 mo	1 dose, \geq 8 weeks after the most recent dose ²
	2 or 3 doses before age 12 mo	1 dose, \geq 8 weeks after the most recent dose ²
	4 doses of PCV7 or other age-appropriate, complete PCV7 schedule	1 supplemental dose, \geq 8 weeks after the most recent dose*

Footnotes, Table 1:

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
- 2) No additional PCV13 doses are indicated for children 12 through 23 months of age who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.

* For children who have underlying medical conditions, a supplemental PCV13 dose is recommended through 71 months of age. For list of conditions, see MMWR 2010;59:9.

Table 2. Recommended schedules for administering doses of PCV13 to children ≥ 24 months of age by PCV vaccination history and age

Age at examination (mos)	Vaccination history: total number of PCV7 and/or PCV13 doses received previously	Recommended PCV13 Regimen ¹
Healthy children 24 through 59 mos	Unvaccinated or any incomplete schedule	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate, complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*
Children 24 through 71 mos with underlying medical conditions	Unvaccinated or any incomplete schedule of <3 doses	2 doses, one ≥ 8 weeks after the most recent dose and another dose ≥ 8 weeks later
	Any incomplete schedule of 3 doses	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*

Footnotes, Table 2:

1) Minimum interval between doses is 8 weeks.

* For children who have underlying medical conditions, a supplemental PCV13 dose is recommended through 71 months of age. For list of conditions, see MMWR 2010;59:9.

This document can be found at the following location:

<http://www.cdc.gov/vaccines/recs/provisional/downloads/pcv13-mar-2010-508.pdf>